DESCOVY Drug Patent Profile

When do Descovy patents expire, and what generic alternatives are available?

Descovy is a drug marketed by Gilead Sciences Inc and is included in one NDA. There are two patents protecting this drug and two Paragraph IV challenges.

This drug has fifty-eight patent family members in forty-two countries.

The generic ingredient in DESCOVY is emtricitabine; tenofovir alafenamide fumarate. There are eighteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the emtricitabine; tenofovir alafenamide fumarate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Descovy

A generic version of DESCOVY was approved as emtricitabine; tenofovir alafenamide fumarate by LUPIN LTD on December 13^th, 2024.

Summary for DESCOVY

International Patents:	58
US Patents:	2
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for DESCOVY

Paragraph IV (Patent) Challenges for DESCOVY

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
DESCOVY	Tablets	emtricitabine; tenofovir alafenamide fumarate	120 mg/15 mg	208215	1	2022-10-31
DESCOVY	Tablets	emtricitabine; tenofovir alafenamide fumarate	200 mg/25 mg	208215	6	2019-11-05

US Patents and Regulatory Information for DESCOVY

DESCOVY is protected by two US patents and two FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gilead Sciences Inc	DESCOVY	emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	208215-002	Jan 7, 2022		RX	Yes	No	8,754,065*PED				Y
Gilead Sciences Inc	DESCOVY	emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	208215-001	Apr 4, 2016	AB	RX	Yes	Yes
Gilead Sciences Inc	DESCOVY	emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	208215-002	Jan 7, 2022		RX	Yes	No

International Patents for DESCOVY

When does loss-of-exclusivity occur for DESCOVY?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

African Regional IP Organization (ARIPO)

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Ecuador

Eurasian Patent Organization

European Patent Office

Finland

Hong Kong

Hungary

India

Israel

Japan

Lithuania

Mexico

Moldova, Republic of

Montenegro

Morocco

New Zealand

Peru

Philippines

Poland

Portugal

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering DESCOVY around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	1808434
Bulgaria	107572
European Patent Office	0984013	Activité antivirale et résolution de 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1, 3-oxathiolane)

Supplementary Protection Certificates for DESCOVY

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1301519	1690012-8	Sweden		PRODUCT NAME: TENOFOVIR ALAFENAMIDE OR A SALT OR SOLVATE THEREOF, IN PARTICULAR TENOFOVIR ALAFENAMIDE FUMARATE; REG. NO/DATE: EU/1/15/1061/001-002 20151123
1301519	300803	Netherlands		PRODUCT NAME: TENOFOVIRALAFENAMIDE OF EEN ZOUT OF SOLVAAT DAARVAN, MET NAME TENOFOVIRALAFENAMIDEFUMARAAT; NATIONAL REGISTRATION NO/DATE: EU/1/15/1061/002 20151123; FIRST REGISTRATION: EU EU/1/15/1061/001 20151123
1663240	15C0071	France		PRODUCT NAME: COMBINAISON DE RILPIVIRINE OU SES FORMES THERAPEUTIQUEMENT EQUIVALENTES PROTEGEES PAR LE BREVET DE BASE TELLES QUE LES SELS PHARMACEUTIQUEMENT ACCEPTABLES DE RILPIVIRINE Y COMPRIS LE SEL D'ACIDE CHLORHYDRIQUE DE RILPIVIRINE AINSI QUE D'EMTRICITABINE; REGISTRATION NO/DATE: EU/1/11/737/001-002 20111128

Investment and Fundamentals Analysis of DESCOVY (Tenofovir Alafenamide / Emtricitabine)

Last updated: February 19, 2026

What is DESCOVY and its market position?

DESCOVY (tenofovir alafenamide/emtricitabine) is an oral fixed-dose combination used primarily for HIV-1 treatment and pre-exposure prophylaxis (PrEP). It is marketed by Gilead Sciences. Launched in 2019, DESCOVY targets a significant segment of HIV management, leveraging Gilead’s dominant position in antiretroviral therapies.

Global HIV treatment market size was valued at approximately $21 billion in 2022 and is projected to grow at around 6% annually through 2030 (Grand View Research, 2022). The PrEP segment is growing faster, driven by increasing awareness and expanded approval in multiple markets.

Market fundamentals influencing investment in DESCOVY

Market size and growth prospects

Segment	Size (2022)	Compound Annual Growth Rate (CAGR)	Drivers
HIV treatment	$21 billion	6%	Rising HIV prevalence, new drug approvals
PrEP	$1.2 billion	12%	Increased adoption, broadening of indications

Growing prevention programs and increased awareness contribute to accelerating PrEP adoption.

Competition landscape

Competitor	Principal Drugs	Market Share (approximated)	Differentiation
Gilead Sciences	DESCOVY, Truvada, Biktarvy	70%	Established portfolio, compliance
Merck	Isentress, Delstrigo	15%	Niche focus, alternative classes
ViiV Healthcare	Juluca, Dovato	10%	Integrated HIV regimens, innovation

Gilead’s dominance stems from early market entry and continuous pipeline expansion.

Pricing and reimbursement

Pricing for DESCOVY varies globally:

• US retail price: approximately $2,380/month (Express Scripts, 2022)
• Reimbursement coverage expands with CDC guidelines and WHO recommendations
• Competitive pricing strategies include patient assistance programs and negotiated formulary inclusion

Pricing pressure is moderate, supported by the drug’s efficacy and safety profile.

Financial fundamentals and R&D pipeline assessment

Revenue and sales patterns

Year	Estimated US Sales	Global Sales	Notes
2021	$1.2 billion	$1.8 billion	Based on Gilead’s fiscal reports
2022	$1.4 billion	$2.0 billion	Growth driven by expanded indication use

Sales are influenced by new patient enrollment, retention rates, and competitive pressures.

Cost structure and profitability

• R&D expenditure in HIV drugs has been stable around 15–20% of revenue
• Gross margin approximately 80%, supported by patent protection and premium pricing
• Operating margins around 35-40%, with ongoing investment in pipeline expansion

Pipeline and combination therapies

Gilead maintains a robust R&D portfolio targeting HIV and other viral infections:

• Long-acting injectables (cabotegravir/rilpivirine): Phase III, expected approval by 2024
• Next-generation tenofovir formulations: in early-stage development
• HIV cure research programs: Phase II trials ongoing

New formulations aim to improve adherence and reduce dosing frequency, key drivers for future growth.

Regulatory considerations

• DESCOVY received FDA approval in 2019 for HIV treatment and PrEP
• Approved in Europe in 2020, expanding market access
• Patent protection extends until at least 2030; generics unlikely before this date due to exclusivity

Regulatory pathway for new formulations and combination regimens remains active, supporting pipeline growth.

Key risks and challenges

• Price competition from generics post-patent expiry
• Regulatory hurdles in emerging markets
• Patient adherence issues affecting real-world efficacy
• Potential market shifts toward long-acting injectables reducing oral therapy demand

Investment implications

Gilead’s strong market position in HIV, steady revenue growth, and ongoing pipeline development make DESCOVY a foundational asset. However, patent cliffs and competitive pressures necessitate vigilance. The transition toward long-acting injectables represents both a threat to current oral therapies and an opportunity via pipeline diversification.

Key Takeaways

• DESCOVY remains a core revenue driver within Gilead’s HIV franchise, with stable growth observed through 2022.
• The HIV treatment and PrEP markets are poised for expansion, driven by increased awareness and new formulations.
• Competition, especially from generic entrants post-2029, poses a significant risk.
• R&D investments in long-acting injectables and next-generation drugs aim to future-proof growth.
• Regulatory and reimbursement policies continue to support DESCOVY’s market penetration but require careful monitoring.

FAQs

1. When is DESCOVY expected to face generic competition? Gilead’s patents for DESCOVY expire around 2030, after which generics could enter the market.

2. How does DESCOVY compare to other HIV therapies? It offers a better safety profile and fewer side effects than earlier formulations like Truvada, with similar efficacy.

3. What is Gilead’s pipeline focusing on? Long-acting injectable treatments, next-generation antiretrovirals, and HIV cure research.

4. Could price competition significantly impact DESCOVY? Yes. Once patent protection lapses, generics are likely to reduce prices and market share.

5. What market trends could influence DESCOVY’s future? Adoption of long-acting injectables, regulatory approvals in emerging markets, and changes in reimbursement policies.

---

References

1. Grand View Research. (2022). HIV Treatment Market Size, Share & Trends Analysis. Retrieved from [URL]
2. Gilead Sciences Inc. Annual Report 2022. [URL]
3. Express Scripts. (2022). Drug Pricing Reports. [URL]
4. FDA. (2019). DESCOVY Approval Announcement. [URL]